

Docket # (FHFAID)	Member	City	State
13260	Bank of Eastern Oregon	Heppner	OR
55342	Great Western Insurance Company	Ogden	UT
55117	Transportation Alliance Bank, Inc.	Ogden	UT
55245	Granite Federal Credit Union	Salt Lake City	UT
55213	Cyprus Credit Union	West Jordan	UT
55118	Great Northwest Credit Union	Aberdeen	WA
4347	Riverview Community Bank	Camas	WA
14623	The Bank of Washington	Edmonds	WA
16274	Fife Commercial Bank	Fife	WA
1925	Olympia FS & LA	Olympia	WA
16193	TwinStar Credit Union	Olympia	WA
1528	First FS & LA of Port Angeles	Port Angeles	WA
16484	Seattle Savings Bank	Seattle	WA
16506	Our Community Federal Credit Union ..	Shelton	WA
921	Yakima FS & LA	Yakima	WA
55069	Solarity Credit Union	Yakima	WA
3903	Buffalo Federal Bank	Buffalo	WY
10647	Hilltop National Bank	Casper	WY
55077	Wyhy Credit Union	Cheyenne	WY
3790	Big Horn Federal Savings Bank	Greybull	WY
15949	Oregon Trail Bank	Guernsey	WY
9491	Rocky Mountain Bank	Rock Springs	WY
13484	RSNB Bank	Rock Springs	WY
15713	Pinnacle Bank—Wyoming	Torrington	WY

II. Public Comments

To encourage the submission of public comments on the community support performance of Bank members, on or before November 17, 2014, each Bank will notify its Advisory Council, nonprofit housing developers, community groups and other interested parties in its district of the members of the Bank selected for this review cycle. 12 CFR 1290.2(b)(2)(ii). In reviewing a member for community support compliance, FHFA will consider any public comments it has received concerning the member. 12 CFR 1290.2(d). To ensure consideration by FHFA, comments concerning the community support performance of members selected for this review cycle must be submitted to FHFA, either by electronic mail to hmgcommunitysupportprogram@fhfa.gov, or by fax to 202-649-4130, on or before December 15, 2014.

Dated: October 27, 2014.

Melvin L. Watt,

Director, Federal Housing Finance Agency.

[FR Doc. 2014-25970 Filed 10-30-14; 8:45 am]

BILLING CODE 8070-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Bijan Ahvazi, Ph.D., National Institutes of Health: Based on the report of an investigation conducted by the National Institutes of Health (NIH) and additional analysis by ORI in its oversight review, ORI found that Dr. Bijan Ahvazi, former Director of the Laboratory of X-ray Crystallography, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, engaged in research misconduct in research supported by the Intramural Program at NIAMS, NIH.

ORI found that Respondent engaged in research misconduct by falsifying data related to or in the following published papers:

1. Ahvazi, B., Boeshans, K.M., Idler, W., Baxa, U., & Steinert, P.M. "Structural basis for the coordinated regulation of transglutaminase 3 by guanine nucleotides and calcium/magnesium." *J. Biol. Chem.* 279(8):7180-92, 2004 Feb 20 (withdrawn) (hereinafter "*JBC* 2004a")

2. Ahvazi, B., Boeshans, K.M., & Steinert, P.M. "Crystal structure of transglutaminase 3 in complex with BMP: Structural basis for nucleotide specificity." *J. Biol. Chem.* 279:26716-25, 2004 (withdrawn) (hereinafter "*JBC* 2004b")

3. Ahvazi, B., Boeshans, K.M., Idler, W., & Cooper, A.J.L. "Crystal structure of transglutaminase 3-cystamine complex: Binding of two cystamines to the nucleotide-binding pocket. M6:06060,

Submitted to *J. Biol. Chem.*, 2006 (rejected) (hereinafter "*JBC* 2006").

Specifically, ORI finds that Respondent:

1. Falsely labeled Figure 3A in *JBC* 2004b representing an isothermal calorimetric titration (ITC) experiment using guanine monophosphate (GMP) and transglutaminase 3 (TGase 3) when the figure was actually a relabeled version of an unrelated experiment that Respondent previously published as Figure 1A in *JBC* 2004a.

2. falsified Figure 4B, Figure 4C, and Figure 6D in *JBC* 2004b and Figure 5E in *JBC* 2006, by altering the original data in the following ways to represent the desired experiment:

- Falsified Figure 4B in *JBC* 2004b, by adding multiple data points to titration curves for four different concentrations of TGase 3 bound by different concentrations of tagged GTPγS and deleting two (2) outlying data points from one of the curves
- falsified Figure 4C in *JBC* 2004 b, representing a competition assay for the release of tagged GTPγS bound to TGase 3, by (1) falsely claiming that the release of the tagged nucleotide occurred with the addition of untagged GMP, when the result was from an assay using untagged GDP, (2) adding additional data points onto the titration curves, and (3) altering the scale of the abscissa
- falsified Figure 6D in *JBC* 2004b, by using the false Figure 4B to also represent an additional competition experiment using unmodified nucleotide analog compounds and

ATP; specifically, Respondent (1) falsified the units and labels of the axes, (2) falsified the labels of the curves, and (3) vertically inverted the curves

- d. falsified Figure 5E in the *JBC* 2006 manuscript, representing a competition experiment for the release of tagged GTP γ S bound to TGase 3 with the addition of cystamine, when the actual experiment was a competition experiment with the addition of untagged nucleotides.

Dr. Ahvazi has entered into a Voluntary Settlement Agreement (Agreement) and has voluntarily agreed for a period of two (2) years, beginning on October 7, 2014:

(1) To have his U.S. Public Health Service (PHS) research supervised and to notify any employer(s)/institution(s) at which he may participate in PHS funded projects of the terms of his supervision; Respondent agrees that prior to the submission of an application for PHS support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research; Respondent agrees that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agrees to maintain responsibility for compliance with the agreed upon supervision plan;

(2) that any institution employing him to work on PHS-supported projects shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; and

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite

750, Rockville, MD 20852, (240) 453-8200.

Donald Wright,

Acting Director, Office of Research Integrity.

[FR Doc. 2014-25887 Filed 10-30-14; 8:45 am]

BILLING CODE 4150-31-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Intent To Award Ebola Response Outbreak Funding to Eligible Ministries of Health and Their Bona Fide Agents

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: This notice provides public announcement of CDC's intent to award Ebola appropriations to select Ministries of Health and their bona fide agents for response to the Ebola outbreak funding. This award was proposed in Fiscal Year (FY) 2015 under funding opportunity announcement GH14-1418, "Protecting and Strengthening Public Health Impact, Systems, Capacity, and Security."

This notice replaces the Notice of Intent to award Ebola Response outbreak funding to eligible Ministries of Health and their bona fide agents which was published on October 22, 2014 (79 FR 63126, October 22, 2014). CDC is correcting the application date, award dates, amount of funding available, and one of the points of contact.

Catalogue of Federal Domestic Assistance Number (CFDA): 93.318.

Authority: Public Health Service 301(a) and 307 as amended [42 U.S.C 241 and 242].

Multiple awards may be awarded to grantees totaling \$300,000 to \$1,500,000 per award for the Ebola response outbreak.

Funding is appropriated under the Continuing Appropriations Resolution, 2015, Public Law 113-164, 128 Stat. 1867 (2014).

DATES: Anticipated award date is 12/11/2014.

Application Due Date: 12/1/2014.

Project Number is CDC-RFA-GH14-1418.

ADDRESSES: CDC has waived the Grants.gov electronic submission process for this requirement. Recipients are hereby authorized to submit a paper copy application for (CDC-RFA-GH14-1418) via Express Mail (i.e. FedEx, UPS,

or DHL) and send the application via email. Mailed applications must be addressed to Dionne Bounds, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, telephone (770) 488-2082, or email at DBounds@cdc.gov. The application must include a detailed line-item budget and justification to support the Ebola activities from December 11, 2014 to September 29, 2015. Please download the following to complete the application package: http://apply07.grants.gov/apply/forms/sample/SF424_2_1-V2.1.pdf—Application Package; <http://www.cdc.gov/od/pgo/funding/docs/CertificationsForm.pdf>—Certifications; http://www.cdc.gov/od/pgo/funding/grants/Budget_Preparation_Guidelines_8-2-12.docx—CDC-IGO Budget Guidelines; <http://apply07.grants.gov/apply/forms/sample/SF424A-V1.0.pdf>—SF-424A Budget Information.

All applications must be submitted to and received by the Grants Management Officer (GMO) no later than 11:59 p.m. EST on December 1, 2014 and please provide the GMO a PDF version of the application by email to the following email address: ogsghebolaresponse@cdc.gov subject line: CDC-RFA-GH14-1418.

Applicants will be provided with the Funding Opportunity Announcement (FOA) and additional application submission guidance via email notification. Applicants may contact the POCs listed with questions regarding the application process.

FOR FURTHER INFORMATION CONTACT:

For programmatic or technical assistance: Kawi Mailutha, Project Officer, Department of Health and Human Services, Centers for Disease Control and Prevention, 1600 Clifton Rd. MS E-29, Atlanta, GA 30333, Telephone: 404-639-8093, E-Mail: KMailutha@cdc.gov.

For financial, awards management, or budget assistance: Dionne Bounds, Grants Management Officer, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, Telephone (770) 488-2082, Email: DBounds@cdc.gov.

SUPPLEMENTARY INFORMATION: The purpose of this notice is to solicit applications from eligible Ministries of Health and their bona fide agents to quickly arrest the spread of the Ebola virus in West Africa and contain the disease as quickly as possible. The funding will support the impacted countries and the surrounding countries to combat this health crisis. This funding will target the following countries: Liberia, Sierra Leone, Guinea,